A Randomized, Double Blind Study to Compare the Effects of Aleglitazar and Actos on Glomerular Filtration Rate and Other Parameters of Renal Function in Patients With Type 2 Diabetes.

Trial Profile

A Randomized, Double Blind Study to Compare the Effects of Aleglitazar and Actos on Glomerular Filtration Rate and Other Parameters of Renal Function in Patients With Type 2 Diabetes.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2016

At a glance

  • Drugs Aleglitazar (Primary) ; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms SESTA-R
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Sep 2011 Results published in the International Journal of Cardiology.
    • 20 May 2009 Actual end date changed from Nov 2008 to Apr 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top